News
Astrazeneca: In the BAXHTN Phase III trial, baxdrostat resulted in a clinically significant reduction in patients' systolic blood pressure. Astrazeneca will apply for approval for this drug by the end of the year
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments